Doctors Issue Urgent Warning About Popular Weight Loss Drugs Before Surgery

Health Points

• GLP-1 medications like Ozempic and Wegovy may increase aspiration risk during anesthesia if not stopped before surgery
• Medical societies now recommend stopping these drugs 1-2 weeks prior to procedures requiring sedation
• Patients should inform all healthcare providers about GLP-1 use, even if prescribed for diabetes rather than weight loss

Millions of Americans taking popular weight loss medications may face serious complications during surgery if they don’t stop the drugs in advance, leading medical experts are now cautioning.

GLP-1 receptor agonists—including Ozempic, Wegovy, Mounjaro, and Zepbound—have revolutionized weight management and diabetes treatment in recent years. But anesthesiologists have identified a potentially dangerous side effect: these medications significantly slow stomach emptying, which can lead to aspiration during procedures requiring anesthesia or sedation.

Aspiration occurs when stomach contents enter the lungs during anesthesia, potentially causing pneumonia, lung damage, or even death. The risk exists even when patients have fasted as instructed before surgery.

We’re seeing patients who have followed all pre-operative fasting instructions, but because of these medications, their stomachs still contain significant food residue hours or even days after their last meal, explained Dr. Michael Champeau, president of the American Society of Anesthesiologists, in a statement to healthcare providers.

The American Society of Anesthesiologists issued updated guidance recommending patients stop daily GLP-1 medications one day before surgery and weekly formulations one week prior. The American Society of Gastrointestinal Endoscopy goes further, suggesting weekly drugs be discontinued two weeks before endoscopic procedures.

These recommendations have created new challenges for surgical scheduling and patient education. Many patients take these medications for diabetes management, not just weight loss, complicating the decision to pause treatment.

This isn’t about stopping the medication permanently—it’s about timing your doses appropriately before any procedure involving sedation, noted Dr. Ion Hobai, an anesthesiologist at Massachusetts General Hospital.

Healthcare advocates emphasize that patients bear responsibility for disclosing all medications to their surgical teams, including drugs prescribed by different physicians. The explosive popularity of GLP-1 medications means many surgeons and anesthesiologists may not think to ask specifically about these drugs.

Some patients obtain these medications through telemedicine services or weight loss clinics that may not coordinate with their primary care physicians. This fragmented care increases the risk that surgical teams remain unaware of GLP-1 use.

The guidance applies to all procedures requiring anesthesia or deep sedation, from major operations to routine colonoscopies and dental surgery. Even cosmetic procedures performed in office settings could pose risks.

Medical professionals stress that patients should not independently decide to stop these medications without consulting their prescribing physician. Diabetic patients especially need guidance on managing blood sugar during the medication pause.

The key message is communication—tell every doctor involved in your care about every medication you’re taking, no matter who prescribed it or why, emphasized Dr. Champeau.

For patients already scheduled for surgery, calling the surgical facility to discuss GLP-1 use may be necessary. Some procedures may need rescheduling to allow adequate washout time for these medications.

The American Society of Anesthesiologists has created patient information resources about GLP-1 medications and surgery, available through their website. They recommend patients bring complete medication lists, including supplements and over-the-counter drugs, to all pre-operative appointments.

As these medications become increasingly common for both diabetes and weight management, medical societies continue refining their guidance. Current recommendations represent the best available evidence, but research continues into optimal timing and patient-specific risk factors.

The situation highlights the importance of coordinated care as powerful new medications enter widespread use. What works effectively for chronic disease management may require careful adjustment around acute medical events like surgery.